- $83.81bn
- $101.99bn
- £31.38bn
- 70
- 69
- 83
- 88
REG - GlaxoSmithKline PLC - Medicago GSK phase 2/3 study start
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - ViiV’s cabotegravir superior for HIV prevention
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - GSK sets new environmental goals
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Total Voting Rights
AnnouncementREG - GlaxoSmithKline PLC - Holding(s) in Company
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
AnnouncementREG - GlaxoSmithKline PLC - 3rd Quarter Results
AnnouncementREG - GlaxoSmithKline PLC - Sanofi and GSK support COVAX - 200m vaccine doses
AnnouncementREG - GlaxoSmithKline PLC - Holding(s) in Company
AnnouncementREG - GlaxoSmithKline PLC - Positive CHMP opinion ViiV long-acting HIV regimen
AnnouncementREG - Jupiter Asset Mgmnt - Portfolio Update
AnnouncementREG - GlaxoSmithKline PLC - Director/PDMR Shareholding
Announcement